A detailed history of Black Rock Inc. transactions in Generation Bio Co. stock. As of the latest transaction made, Black Rock Inc. holds 3,048,849 shares of GBIO stock, worth $8.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,048,849
Previous 3,168,415 3.77%
Holding current value
$8.6 Million
Previous $5.23 Million 137.38%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$1.73 - $4.07 $206,849 - $486,633
-119,566 Reduced 3.77%
3,048,849 $12.4 Million
Q4 2023

Feb 13, 2024

SELL
$0.91 - $3.35 $168,642 - $620,825
-185,321 Reduced 5.53%
3,168,415 $5.23 Million
Q3 2023

Nov 13, 2023

SELL
$3.65 - $6.9 $668,774 - $1.26 Million
-183,226 Reduced 5.18%
3,353,736 $12.7 Million
Q2 2023

Aug 11, 2023

BUY
$3.5 - $5.67 $317,093 - $513,690
90,598 Added 2.63%
3,536,962 $19.5 Million
Q1 2023

May 12, 2023

SELL
$3.61 - $7.01 $944,747 - $1.83 Million
-261,703 Reduced 7.06%
3,446,364 $14.8 Million
Q4 2022

Feb 13, 2023

BUY
$3.66 - $6.77 $336,800 - $622,988
92,022 Added 2.54%
3,708,067 $14.6 Million
Q3 2022

Nov 14, 2022

BUY
$4.68 - $8.34 $533,903 - $951,443
114,082 Added 3.26%
3,616,045 $19.2 Million
Q2 2022

Aug 12, 2022

BUY
$4.87 - $9.41 $1.62 Million - $3.13 Million
333,150 Added 10.51%
3,501,963 $23 Million
Q1 2022

May 12, 2022

BUY
$4.16 - $7.76 $4,813 - $8,978
1,157 Added 0.04%
3,168,813 $23.3 Million
Q4 2021

Feb 10, 2022

BUY
$5.99 - $24.97 $254,676 - $1.06 Million
42,517 Added 1.36%
3,167,656 $22.4 Million
Q3 2021

Nov 09, 2021

BUY
$20.0 - $27.43 $5.5 Million - $7.54 Million
274,999 Added 9.65%
3,125,139 $78.3 Million
Q2 2021

Aug 11, 2021

BUY
$24.34 - $38.34 $69.4 Million - $109 Million
2,850,140 New
2,850,140 $76.7 Million

Others Institutions Holding GBIO

About Generation Bio Co.


  • Ticker GBIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,011,200
  • Market Cap $166M
  • Description
  • Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was f...
More about GBIO
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.